Vivos Therapeutics (VVOS) FCF Margin (2020 - 2026)
Vivos Therapeutics (VVOS) reported FCF Margin of 117.25% for Q1 2026, up 1265.0% year-over-year from 8.59% in Q1 2025, and up 44.9% on a QoQ basis from 212.81% in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of FCF Margin data on file, last reported at 117.25% in Q1 2026.
- Quarterly FCF Margin rose 1265.0% year-over-year to 117.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 115.28% (down 1609.0% YoY) and the FY2025 annual result came in at 117.23%, down 2902.0% from the prior year.
- FCF Margin rose to 117.25% in Q1 2026 per VVOS's latest filing, from 212.81% in the prior quarter.
- Across five years, FCF Margin topped out at 60.7% in Q3 2025 and bottomed at 212.81% in Q4 2025.
- The 5-year median for FCF Margin is 98.2% (2023), against an average of 108.48%.
- The widest annual swing landed in 2023, when FCF Margin soared 7865 bps; it then tumbled 12885 bps in 2025.
- Tracing VVOS's FCF Margin over 5 years: stood at 80.68% in 2022, then gained by 19 bps to 65.02% in 2023, then retreated by 29 bps to 83.96% in 2024, then tumbled by 153 bps to 212.81% in 2025, then soared by 45 bps to 117.25% in 2026.
- Per Business Quant, the three latest VVOS FCF Margin figures stand at 117.25% (Q1 2026), 212.81% (Q4 2025), and 60.7% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 8.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 6.89% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 25.51% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 3.29% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -1.28% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.68% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 37.67% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 3.98% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.44% |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | -117.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.25% |
| Dec 31, 2025 | -138.44% |
| Sep 30, 2025 | -60.70% |
| Jun 30, 2025 | -111.91% |
| Mar 31, 2025 | -129.91% |
| Dec 31, 2024 | -82.88% |
| Sep 30, 2024 | -113.78% |
| Jun 30, 2024 | -77.95% |
| Mar 31, 2024 | -77.54% |
| Dec 31, 2023 | -83.13% |
| Sep 30, 2023 | -84.88% |
| Jun 30, 2023 | -84.21% |
| Mar 31, 2023 | -93.05% |
| Dec 31, 2022 | -81.01% |
| Sep 30, 2022 | -141.31% |
| Jun 30, 2022 | -121.99% |
| Mar 31, 2022 | -170.69% |
| Dec 31, 2021 | -50.48% |
| Sep 30, 2021 | -98.97% |
| Jun 30, 2021 | -110.43% |
| Mar 31, 2021 | -120.71% |
| Dec 31, 2020 | -109.32% |
| Sep 30, 2020 | -20.85% |
| Jun 30, 2020 | -29.30% |
| Mar 31, 2020 | -13.83% |